Factors Associated With Sub - Targeted Therapeutic Dose Of Renin - Angiotensin Blockage Among Chronic Heart Failure With Reduced Ejection Fraction Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 396
- 主要终点
- factors associated with sub - target dose of ACEIs,ARBs,ARNI
研究概览
简要总结
Objective: To analyze factors associated with Thai heart failure with reduced ejection fraction patients who received sub-target doses of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs).
Methods: The retrospective cohort study was designed to collect data on Thai heart failure with reduced ejection fraction patients at Out-patient Clinic, Trat Hospital and Phrapokklao Hospital from January 2016 to December 2020. Thirteen factors were analyzed to determine their association with the sub-target group.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who were first diagnosed be heart failure with left ventricular ejection fraction less than 40%.
- •Received one of ACEIs,ARBs,ARNI drugs.
排除标准
- •Electronic medical records was not complete enough to analyse.
- •Patients who had history of heart transplantation or had heart transplantation plan in last 12 months.
研究组 & 干预措施
Sub - target dose group
Patients who received sub - target dose of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs).
干预措施: Renin-Angiotensin System Inhibitor (Drug)
Target dose group
Patients who received target dose or maximal tolerated dose of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs)
干预措施: Renin-Angiotensin System Inhibitor (Drug)
结局指标
主要结局
factors associated with sub - target dose of ACEIs,ARBs,ARNI
时间窗: 12 months
factors associated with Thai heart failure with reduced ejection fraction patients who received sub-target doses of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs).
次要结局
未报告次要终点